Vaiomer - Physiogenex partnership to provide integrated services to nutrition and pharma Cies.


Physiogenex, a leading contract research organization providing validated nutritional animal models to evaluate compounds targeting metabolic diseases, and Vaiomer, a pioneer in microbiome science focusing on the development of novel biomarkers, therapeutic targets and drugs for cardiometabolic diseases, announced they have entered into commercial partnership.

Combining Physiogenex’s nutritional animal models and Vaiomer’s expertise in blood and tissue microbiome characterization, the two companies offer with this partnership advanced preclinical and researchservices, providing a one-of-a-kind platform to evaluate the proof of efficacy of nutraceuticals or drugs targeting obesity, type 2 diabetes and related cardio-metabolic complications. The Companies are also pursuing collaborative R&D programs to establish innovative preclinical models to expand the offering.

Dr. Michael Courtney, CEO of Vaiomer, said "The integrated offering provided by this partnership reflects the intimate relationship between the microbiome and metabolic dysregulation. Our combined technologies reply to growing demand from customers in the nutrition and pharmaceutical industries."

"We are delighted to extend our partnership with Vaiomer, and look forward to provide the most robust and valuable preclinical data to our customers by combining our validated nutritional animal models with Vaiomer’s innovative services", commented Dr. Thierry Sulpice, CEO/CSO of Physiogenex.

About Vaiomer

Based on its pioneering research on the role of tissue microbiota in the initiation of the inflammatory cascade leading to metabolic disorders, Vaiomer’s vocation is to contribute to the discovery of innovative biomarkers, therapeutic targets and products for the early prognosis, prevention and treatment of cardiometabolic diseases.
In addition, Vaiomer has developed an innovative service offering for the characterization of blood- and tissue-associated microbiota and bacterial translocation for preclinical and clinical studies.

Please visit our website for more information at

About Physiogenex

Physiogenex is a leading research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and cardiovascular complications.

To learn more about Physiogenex, visit